Sensyne Health PLC (LON:SENS) has teamed up with Oxford University to provide the data analysis for a phase II clinical study of a blockbuster arthritis drug that is being re-purposed to tackle the potentially fatal symptoms of COVID-19.
Researchers are assessing whether anti-TNF treatment adalimumab, which is sold by AbbVie as Humira, can halt the progression of coronavirus – stopping it well before it causes respiratory failure.
The trial is funded by the COVID-19 Therapeutics Accelerator, set up by the Wellcome Trust, the Bill and Melinda Gates Foundation and Mastercard, with help from public and philanthropic donors.
Using Sensyne's software, symptom information, vital signs and daily activity information will be collected remotely from clinical study subjects in care homes.
This will be followed by a phase of exploratory data analysis using the firm’s machine learning algorithms.
The software is based on the CVm-Health application for tracking COVID-19 symptoms launched earlier this year.
Chief executive Lord Drayson said: "Sensyne is at the forefront of developing advanced remote monitoring software and clinical AI tools that enable clinical research to be undertaken during the new circumstances caused by the COVID-19 pandemic.
“We are delighted to be working with the University of Oxford on this important new trial of Adalimumab, pioneering new clinical research techniques in the community environment."